ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025

The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and […]

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025 Read Post »

Telehealth in rural areas: Bridging the gaps through policy drivers, Intelligent Hospital, December 2025 issue

In an article published in the December 2025 issue of Intelligent Hospital on the challenges of telehealth adoption in rural communities, the authors examine why telehealth uptake remains limited outside urban areas despite its growing role in modern healthcare. The study explains that although technology has transformed health services by improving clinical capabilities and patient

Telehealth in rural areas: Bridging the gaps through policy drivers, Intelligent Hospital, December 2025 issue Read Post »

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025

A new study published recently on CHEST evaluated whether the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)—a patient-reported version of the World Health Organisation (WHO) Functional Class—captures functional status in a way that reflects patients’ real experiences. Study Overview Eighty-nine adults with pulmonary hypertension (Groups 1–5) from the Cleveland Clinic and Mayo Clinic completed an online

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025 Read Post »

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

The Pulmonary Vascular Research Institute (PVRI) launches its Pulmonary Hypertension Patient Engagement & Empowerment Series

The Pulmonary Hypertension Patient Engagement & Empowerment Series is a new evidence-based resource designed to help people living with pulmonary hypertension and their families and carers to be more informed, confident, and empowered. The series was developed by Pulmonary Vascular Research Institute IDDI Patient Engagement & Empowerment Workstream. The series explores 11 core themes, including:

The Pulmonary Vascular Research Institute (PVRI) launches its Pulmonary Hypertension Patient Engagement & Empowerment Series Read Post »

What Do Patients Think About Right Heart Catheterizations? Four patients share what it means to them, Journal of Cardiac Failure, November 21, 2025

Right heart catheterization often marks a turning point in the journey of people living with pulmonary hypertension. Yet an important question remains: what do patients actually experience during this procedure, and what kind of support do they need once it’s over? A paper published recently on the Journal of Cardiac Failure features insights from four

What Do Patients Think About Right Heart Catheterizations? Four patients share what it means to them, Journal of Cardiac Failure, November 21, 2025 Read Post »

PF-07868489: Pfizer’s New Biologic Enters Phase 2 for Pulmonary Arterial Hypertension

Pfizer has a new study ongoing on PF-07868489, a recombinant human IgG1 antibody that targets bone morphogenetic protein 9 (BMP9) and is administered through subcutaneous route for the treatment of PAH. PF-07868489 is currently in Phase 2 development and has received Orphan Drug designation in the US.  The study (NCT06137742) has two parts: Part A: An

PF-07868489: Pfizer’s New Biologic Enters Phase 2 for Pulmonary Arterial Hypertension Read Post »

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025 

A review recently published in the European Respiratory Journal Open Research provides the latest evidence on drug- and toxin-associated pulmonary arterial hypertension, offering clinicians updated guidance on recognition, diagnosis, and management of this pulmonary arterial hypertension subtype (see below for the most recent pulmonary arterial hypertension classification, at 1.3) The first World Health Organization (WHO)

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025  Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

“Health at a Glance: Europe 2024” report by the Organisation for Economic Co-operation and Development (OECD) analyzes critical challenges confronting European health systems

The Organisation for Economic Co-operation and Development (OECD) “Health at a Glance: Europe 2024” report analyzes critical challenges confronting European health systems following the COVID-19 pandemic. Two thematic chapters anchor the publication. The opening chapter delivers an in-depth analysis of Europe’s health workforce crisis. It examines the root causes of personnel shortages and outlines policy

“Health at a Glance: Europe 2024” report by the Organisation for Economic Co-operation and Development (OECD) analyzes critical challenges confronting European health systems Read Post »

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025

Pulmonary veno-occlusive disease (PVOD) is a rare, severe World Health Organisation Group 1 pulmonary arterial hypertension (PAH) subtype with poor survival. pulmonary arterial hypertension-targeted vasodilators can cause life-threatening pulmonary edema in Pulmonary veno-occlusive disease, underscoring the need for diagnostic tools to distinguish it from other pulmonary arterial hypertension subtypes The findings of a study recently

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025 Read Post »

Inhibikase Therapeutics Phase 3 study on IKT-001 – an anti-proliferative tyrosine kinase inhibitor – expected to be initiated in the first quarter of 2026

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company has announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in pulmonary arterial hypertension The Phase 3 study, named IMPROVE-PAH, is expected to be initiated in the first quarter of 2026. IKT-001 is an investigational novel pro-drug of imatinib mesylate. Imatinib is

Inhibikase Therapeutics Phase 3 study on IKT-001 – an anti-proliferative tyrosine kinase inhibitor – expected to be initiated in the first quarter of 2026 Read Post »

“Heart Works” – phaware® – a New Pulmonary Hypertension App from Phaware Global Association®

“Heart Works” key features: Real-time health data tracking: including advanced quality-of-life surveys and 6-minute walk tests, allowing patients to closely monitor their progression. Access to Phaware resources: 500+ curated phaware® podcasts, webinars, and expert interviews on pulmonary hypertension. Access to international resources: Thanks to partnerships with leading organizations including Stanford Wall Center, University of Alberta,

“Heart Works” – phaware® – a New Pulmonary Hypertension App from Phaware Global Association® Read Post »

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025

Combined post- and precapillary pulmonary hypertension (CpcPH) represents a subset of pulmonary hypertension due to left heart disease (PH-LHD), also known as World Health Organisation Group 2 pulmonary hypertension. There are currently no treatments specifically approved for this condition. The CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025 Read Post »

Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025

The 6th “Journées du Réseau Français de l’Hypertension Pulmonaire” (JRF-HTP), held in October 2024, provided a review of the evolving landscape in pulmonary hypertension (PH). The meeting brought together clinicians and researchers to exchange on the most recent scientific, clinical, and organizational advances in pulmonary hypertension. We are proud that a patient advocate was included as co-author,

Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025 Read Post »

Publication of a new European Medicines Agency (EMA) booklet on medicine safety monitoring

The European Medicines Agency (EMA) has published a new booklet on the safety monitoring of medicines in the European Union. It provides an overview of how the European Medicines Agency and European Union Member States work to ensure that medicines used across Europe remain safe throughout their lifecycle.  The booklet is published on a new

Publication of a new European Medicines Agency (EMA) booklet on medicine safety monitoring Read Post »

Tacrolimus in Solid Organ Transplantation: A 30-Year Journey, Transplantation, March 2021

Tacrolimus (FK506), discovered in 1984 from Japanese soil fungus, revolutionized organ transplantation. Dr. Thomas Starzl’s pioneering work at the University of Pittsburgh demonstrated dramatic improvements over cyclosporine: liver graft survival increased from 65.5% to 86.2%, with rejection rates dropping to 1-2%. The Food and Drug Administration (FDA) approval followed for liver (1994), kidney (1997), and

Tacrolimus in Solid Organ Transplantation: A 30-Year Journey, Transplantation, March 2021 Read Post »

New edition of emPHasis, the UK Pulmonary Hypertension Association (PHA UK)’s magazine is just out

The two main highlights of this edition are the report of the UK Pulmonary Hypertension survey on what symptoms affect patients most (pages 9-12) and the association’s 25th anniversary celebrations in Birmingham (pages 16-18). For the survey there were 232 responses from patients and 35 responses from caregivers. KEY FINDINGS – THE PATIENT VIEW MOST

New edition of emPHasis, the UK Pulmonary Hypertension Association (PHA UK)’s magazine is just out Read Post »

Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease (PH-CHD), Expert Review of Respiratory Medicine, October 30, 2025

Pulmonary hypertension associated with congenital heart disease (PAH-CHD) is one of the most common causes of pulmonary hypertension in children. Patients fall into different subgroups, each requiring specific treatment approaches. According to an article recently published in the Expert Review of Respiratory Medicine current management is clear for two groups: The challenge The management of

Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease (PH-CHD), Expert Review of Respiratory Medicine, October 30, 2025 Read Post »

Lung Transplant Allocation System Challenges for Pulmonary Arterial Hypertension (PAH) Patients, Letter to the Editor, Transplant International, October 28, 2025

Pulmonary arterial hypertension patients face unique challenges in lung transplantation. Unlike patients with other lung diseases, they often have relatively normal lung function tests but are in critical condition due to heart failure. This means they receive low priority scores in the standard Lung Allocation Score (LAS) system, which was designed primarily for patients with

Lung Transplant Allocation System Challenges for Pulmonary Arterial Hypertension (PAH) Patients, Letter to the Editor, Transplant International, October 28, 2025 Read Post »

TRANSLATE »
Scroll to Top